Ribeiro MFS, Alessi JVM, Oliveira LJC, et al. - The activity and tolerability of alectinib 600 mg twice daily in advanced and chemo-refractory RET-rearranged non-small cell lung carcinomas (NSCLCs) patients treated in a Brazilian institution were retrospectively evalauted and reported in order to report outcomes of four cases of chemo-refractory RET-rearranged NSCLCs treated with alectinib in a single center. The four individuals herein reported were white, female and non-smokers, ranging between 59–66 years of age. However this is a small single center assessment, alectinib was well tolerated and showed clinical activity against advanced RET-rearranged NSCLCs, implying its potential role in this particular subset of malignancies.